4-[5-(3-Iodo-phenyl)-2-(4-methanesulfinyl-phenyl)-1H-imidazol-4-YL]-pyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-[5-(3-Iodo-phenyl)-2-(4-methanesulfinyl-phenyl)-1H-imidazol-4-YL]-pyridine
• 英文别名: 4-[4-(3-iodophenyl)-2-[4-[(R)-methylsulfinyl]phenyl]-1H-imidazol-5-yl]pyridine
• 化学式: C₂₁H₁₆IN₃OS
• 分子量: 485.3
• InChiKey: RXDZANYWRNIAOR-HHHXNRCGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  77.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND A METHOD FOR THE PROPHYLAXIS AND TREATMENT OF THE ADHESION PROCESS
  申请人：Joint Stock Company "Pharmasyntez"

  公开号：EP3569636A1

  公开（公告）日：2019-11-20

  The invention relates to the field of pharmacy, clinical and experimental medicine and veterinary medicine, and in particular to novel inhibitory compounds of a p38 MAP kinase with a structure of the type (I)-(VII) which can be used for the treatment or prophylaxis of adhesion. The invention discloses pharmaceutical compositions containing an effective amount of the substance SB203580 or one of the compounds of the type (I)-(VII) or a combination thereof and a pharmaceutically acceptable carrier, a diluent or an excipient. Also disclosed is the use of the substance SB203580 as an agent having anti-adhesion activity. Also disclosed is: a method for the prophylaxis and/or treatment of a disease or a condition in which there is the possibility of the formation and/or growth of adhesions which makes it possible to dispense with the additional administration of a preparation in the post-operative period.

  本发明涉及药学、临床和实验医学以及兽医学领域，尤其涉及具有(I)-(VII)型结构的新型 p38 MAP 激酶抑制化合物，该化合物可用于治疗或预防粘附。本发明公开了药物组合物，其中含有有效量的 SB203580 物质或 (I)-(VII) 型化合物之一或其组合物以及药学上可接受的载体、稀释剂或赋形剂。还公开了物质 SB203580 作为具有抗粘附活性的制剂的用途。还公开了：一种预防和/或治疗有可能形成和/或生长粘连的疾病或病症的方法，该方法使术后无需额外服用制剂成为可能。